Innovative Industrial Properties (IIPR) Q1 2026 Earnings
Reported May 4, 2026 at 5:13 PM ET · SEC Source
Q1 26 EPS
$1.02
MISS 4.97%
Est. $1.07
Q1 26 Revenue
$69.0M
BEAT +4.16%
Est. $66.2M
vs S&P Since Q1 26
+11.8%
BEATING MARKET
IIPR +14.8% vs S&P +3.0%
Market Reaction
Did IIPR Beat Earnings? Q1 2026 Results
Innovative Industrial Properties delivered a mixed first quarter for 2026, posting revenue that cleared Wall Street's bar while earnings fell short. The cannabis-focused REIT reported $69.00 million in revenue, topping the $66.24 million consensus by… Read more Innovative Industrial Properties delivered a mixed first quarter for 2026, posting revenue that cleared Wall Street's bar while earnings fell short. The cannabis-focused REIT reported $69.00 million in revenue, topping the $66.24 million consensus by 4.16%, though the figure still marked a 3.8% decline from a year earlier as tenant defaults, totaling roughly $6.90 million in lost revenue, weighed on results. Diluted EPS came in at $1.02, missing the $1.07 consensus by 4.97%, while AFFO slipped to $1.88 per share from $1.94 a year ago. The company showed leasing momentum, executing nearly 400,000 square feet of deals year-to-date with tenants including Curaleaf and Grown Rogue, and maintained a 97.8% leased portfolio. Management is actively resolving legacy defaults and has reached tentative arrangements for four 4Front Ventures properties totaling approximately 488,000 square feet, expected to go into effect by year-end 2026. With $291.21 million in unsecured notes maturing in May 2026, IIP is pursuing nearly $130.00 million in additional debt financings to address that obligation while sustaining its $1.90 quarterly dividend.
Key Takeaways
- • Annual contractual rent escalations on existing leases
- • Rental revenue from property acquired in February 2025
- • New leases executed on existing properties (389,000 sq ft year-to-date)
- • IQHQ life science investment generating $5.5 million in interest and dividend income
- • Security deposit applications of $1.2 million from Battle Green and The Cannabist Company
- • 97.8% operating portfolio leased rate
IIPR Forward Guidance & Outlook
IIP has additional secured and unsecured debt financings underway totaling nearly $130 million, to be used to address the upcoming May 2026 bond maturity ($291.2 million of 5.50% Unsecured Notes) and position the company for growth. The company remains committed to funding up to an additional $95 million of preferred equity in IQHQ in multiple tranches through Q2 2027. Tentative arrangements have been reached with prospective new tenants for four 4Front assets (approximately 488,000 square feet), subject to diligence and licensing, expected to go into effect by year-end 2026. PharmaCann properties in New York, Ohio, and Pennsylvania are mandated for turnover by late May 2026. The U.S. cannabis market is projected to grow at an 8% CAGR from 2025 to 2030, reaching an estimated $43 billion in legal sales. The April 2026 reclassification of medical cannabis to Schedule III removes 280E tax burdens for qualifying operators, potentially improving tenant cash flows.
IIPR YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
IIPR Revenue by Segment
With YoY comparisons, source: SEC Filings
“We are encouraged by the pace of leasing activity year-to-date, including nearly 400,000 square feet of executed leases, which underscores the ongoing demand for our properties. At the same time, we have taken deliberate steps to fortify our balance sheet through equity and debt capital raising activity, and have additional secured and unsecured debt financings underway totaling nearly $130 million, to be used to address our upcoming bond maturity and position us for growth.”
— Alan Gold, Q1 2026 Earnings Press Release
IIPR Earnings Trends
IIPR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
IIPR EPS Trend
Earnings per share: estimate vs actual
IIPR Revenue Trend
Quarterly revenue: estimate vs actual
IIPR Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $1.07 | $1.02 | -4.97% | $69.0M | +4.16% |
| Q4 25 BEAT FY | $1.05 | $1.06 | +1.27% | $66.7M | +1.10% |
| FY Full Year | — | $3.93 | — | $266.0M | — |
| Q3 25 BEAT | $0.90 | $0.97 | +7.38% | $64.7M | +1.51% |
| Q2 25 MISS | $0.91 | $0.86 | -5.84% | $62.9M | -1.50% |